User: Guest

PLASMA PROTEASE C1-INHIBITOR TREATMENT

Global Market Trajectory & Analytics

MCP16695

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

432

Interactions with Platform & by Email *

INTERACTIONS

86

Unique # Participated *

PARTICIPANTS

17

Responses Validated *

VALIDATIONS

8

* Login to view program details and full enterprise executive list.



COVID-19 IMPACT SURVEY MAY 2020

Amid the COVID-19 crisis and the looming economic recession, the Plasma Protease C1-inhibitor Treatment market worldwide will grow by a projected US$6.5 Billion, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 19.8%. C1-Inhibitor, one of the segments analyzed and sized in this study, is forecast to grow at over 18.2% and reach a market size of US$4.7 Billion by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The C1-Inhibitor market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 21.7% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$234.1 Million to the region's size over the next 7 to 8 years. In addition, over US$298.5 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the C1-Inhibitor segment will reach a market size of US$252.7 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Plasma Protease C1-inhibitor Treatment market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 19.8% over the next couple of years and add approximately US$813.5 Million in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Plasma Protease C1-inhibitor Treatment market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others, CSL Ltd.; Pharming Group NV; Sanquin; Shire PLC

SEGMENTS

» Distribution Channel (Hospital Pharmacies, Independent Pharmacies) » Dosage Type (Lyophilized, Liquid/Injectable) » Drug Class (C1-Inhibitor, Kallikrein Inhibitor (Kalbitor), Selective Bradykinin B2 Receptor Antagonist (Firazyr)))

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

VIEW FULL REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com